scholarly journals STUDY OF CORONAVIRUS DISEASE 2019 (COVID-19) VACCINATION IN INDONESIA: A LITERATURE REVIEW

2021 ◽  
Vol 18 (2) ◽  
pp. 65-77
Author(s):  
Theresia Lidia ◽  
Aris Widayati
Keyword(s):  
Clinical Trials ◽  
Side Effects ◽  
Literature Review ◽  
Vaccine Safety ◽  
World Health ◽  
Health Promotion Program ◽  
National Agency ◽  
The Republic ◽  
Health Organization ◽  
Religious Reasons

Research and development of the COVID-19 vaccine give hope to all people to stop the COVID-19 pandemic in the world. This literature review explores the safety and efficacy of the COVID-19 vaccine used in Indonesia and discusses Indonesia's current vaccination process. The primary databases for the reviewed articles were PubMed and Mendeley. Others are official websites, such as World Health Organization (WHO); COVID-19 and National Economic Recovery Committee in Indonesia (KPCPEN); the National Agency of Drug and Food Control (NA-DFC–in Bahasa Indonesia: BPOM) of the Republic of Indonesia; the US Food and Drug Administration (FDA), Clinical Trials.gov, COVID-19 vaccine Tracker, the Indonesian regulations, and guidelines regarding COVID-19. The inclusion criteria of the searched articles were those published from December 2019 to April 30, 2021, and those which discussed vaccines' types, efficacy, and safety. Acceptance of the COVID-19 vaccination is quite high (65%). Refusal was related to vaccine safety (30%); effectiveness (22%); distrust of vaccines (13%); fear of side effects (12%); and religious reasons (8%). The COVID-19 vaccines planned by the Indonesia Government have gone through clinical trials phases I to III. The Coronavac vaccine efficacy showed seroconversion that occurred was 92.4% to 97.4%, and no severe side effects have been reported. The ChAdOx1 nCoV-19 efficacy was 66.7% to 76.0%, and none of the tested participants was hospitalized, serious side effects were very small (0.9% to 1.1%). The mRNA-1273 efficacy was 94.1%, and its reactogenicity was mild to moderate. The BNT162b2 efficacy was ≥ 92%, and no severe or specific safety concerns have occurred. The efficacy of the BBIBPCorV vaccine has not been established. Ongoing phase I, II, and III clinical trials will provide more information on safety and immunogenicity for the BBIBP-CorV. Three of the six vaccines have obtained EUA from BPOM and approval from the Indonesian Ulema Council (MUI). A health promotion program about the safety, efficacy, and the 'halal' of the COVID-19 vaccine; acceleration and ensuring access to the COVID-19 vaccination program are urgent to end this pandemic immediately.

scholarly journals A Minireview of the Promising Drugs and Vaccines in Pipeline for the Treatment of COVID-19 and Current Update on Clinical Trials

2021 ◽  
Vol 8 ◽  
Author(s):  
Jeyanthi Venkadapathi ◽  
Venkat Kumar Govindarajan ◽  
Saravanan Sekaran ◽  
Santhi Venkatapathy
Keyword(s):  
Clinical Trials ◽  
Monoclonal Antibodies ◽  
Viral Vectors ◽  
Antiviral Agents ◽  
Spike Protein ◽  
World Health ◽  
The World ◽  
The Republic ◽  
Health Organization ◽  
Day By Day

The COVID-19 is affecting thousands of peoples day by day and continues to spread across the world. The present review has focused on promising repurposing drugs, including remdesivir, lopinvar/retinovar, favipiravir, hydroxychloroquine, monoclonal antibodies and vaccines against the SARS-CoV-2 infection. Besides, our review has also focused on many organizations that are in the race to develop vaccines using various approaches including DNA, RNA, viral vectors and subunit proteins against this highly contagious respiratory disease. The spike protein is being studied by scientists all over the world to develop potential vaccines. The antiviral drugs, antibodies and vaccines developed by various researchers around the world have entered clinical trials in humans. The current clinical trials for antiviral agents and vaccines with promising outcomes are being discussed. So far, four vaccines developed by the Pfizer-BioNTech vaccine, the Johnson and Johnson vaccine and two AstraZeneca vaccines (produced by SKBio in the Republic of Korea and Serum Institute of India) are approved by the World Health Organization for public use.

scholarly journals A Review of the Antiviral Activity of Ivermectin and Its Use in the Treatment of Coronavirus Disease-2019

2021 ◽  
Vol 6 (1) ◽  
pp. 35-40
Author(s):  
Christabel N. Hikaambo ◽  
◽  
Martin Kampamba ◽  
Fernando Bwalya ◽  
Mutenje Mweemba ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Treatment Guidelines ◽  
Antiviral Agents ◽  
Signs And Symptoms ◽  
World Health ◽  
Treatment Modalities ◽  
Therapeutic Effects ◽  
Hospitalised Patients ◽  
The Republic ◽  
Health Organization

Background The coronavirus disease-2019 (COVID-19) originated in China and was declared a pandemic by the World Health Organization (WHO) on 11th March 2020. Since its emergence in December 2019, there have been challenges in developing drugs that are effective against the virus. Currently, COVID-19 is managed using symptomatic and supportive therapies, antiviral agents, cellular and immunotherapy. Besides, most of the treatment modalities are still under investigation and treatment guidelines vary from one country to another. Ivermectin is among the drugs that are being used as part of treatment guidelines in certain countries like the Republic of Peru. However, the WHO recommends that ivermectin only be used in clinical trials. Aim The authors conducted this review to explore published studies on the possible therapeutic effects of ivermectin against active infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a causative agent of COVID-19. Methods A literature search was conducted using Google Scholar, PubMed and EMBASE for articles published from 2016 to 2021. Search words used included ivermectin, antiviral, COVID-19, efficacy, safety, dosing, lower mortality rate, hospitalised patients and the Boolean operator ‘AND’. Results A few clinical trials have shown that ivermectin is safe for use in humans at specific doses and reduces the severity of the infection. Ivermectin was seen to reduce the signs and symptoms associated with COVID-19 in some studies while others showed no significant reduction. However, more studies must be conducted to ascertain its use in treating COVID-19. Conclusion Since many clinical trials are being conducted on the use of ivermectin to treat COVID-19, full evidence will be used to support its use in humans. Currently, some countries that are using ivermectin for treating COVID-19 have reported it to be effective and reduces morbidity and mortality associated with the disease. Therefore, countries should collaborate and provide full evidence for the use of ivermectin in humans to manage COVID-19.

scholarly journals DETAILED INFORMATION ON FAVIPIRAVIR: DRUG FOR TREATMENT OF SARS-COV-2

2020 ◽  
pp. 13-17
Author(s):  
MONAJI SANJANA REDDY
Keyword(s):  
Clinical Trials ◽  
Side Effects ◽  
Severe Acute Respiratory Syndrome ◽  
World Health Organization ◽  
Respiratory Illness ◽  
World Health ◽  
Genetic Mutations ◽  
Corona Virus ◽  
The World ◽  
Health Organization

Severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) is another name given to pandemic disease COVID-19 that is caused by a newly discovered coronavirus. People infected with coronavirus will experience mild-to-moderate respiratory illness, and it can be seen in a serious stage when comorbidities include along with it. This is now creating a huge pandemic situation all over the world with a huge rate of sufferers, that is, around 9.06 million around the world and about 440 k in India till today according to the World Health Organization. This is a serious condition that should be solved with vaccine only as coronavirus is undergoing mutation it makes difficult to invent a vaccine for it. So far, about 200 genetic mutations have been discovered across the world also in these 198 mutations appeared independently more than once. Due to this pandemic situation, there are so many clinical trials going on in discovering vaccines. Recently, after many trails conducting favipiravir are found to be the most successful in treating any stage of SARS-CoV-2. This article focuses completely on this area, along with its mechanism, side effects, uses, and contraindications.

Reflections on FDA and WHO recommendations concerning clinical trials

1989 ◽  
Vol 4 (2) ◽  
pp. 117-122 ◽  
Author(s):  
J.-F. Dreyfus ◽  
D. Cremniter ◽  
J.D. Guelfi
Keyword(s):  
Clinical Trials ◽  
Drug Users ◽  
Objective Evaluation ◽  
World Health ◽  
Measuring Instruments ◽  
New Techniques ◽  
The Usa ◽  
The One ◽  
Health Organization

SummaryWe are still confronted by numerous different nosographic models and problems concerning the objective evaluation of patients progress during treatment. It is interesting to consider the consequences of this situation in psychiatry which still involves a relative diversity of practical methods used in clinical trials. The recommendations of the USA Food and Drug Administration, on the one hand, constitute a highly structured and precise reference. The World Health Organization, on the other hand, promulgates general recommendations resulting from a compromise designed to satisfy the greatest number of clinicians.Despite the apparently diverse principles and the different practical methods they propose, both those sets of recommendations have been useful in inspiring clinicians to reflect upon these different methodological approaches. The qualities of the inclusion criteria used in the study of patients and the sensitivity of the different measuring instruments have allowed psychotropic drug users as well as producers to recognize the need for a certain rigour in clinical trials.The FDA and WHO guidelines have certainly improved the quality of clinical trials in psychopharmacology. However, they also represent a source of resistance to innovation.A series of consensus meetings to first reconcile US and European points of view and later to include new techniques in the recognized sets of methods would therefore be helpful.

Kesehatan Mental Mahasiswa Fakultas Kedokteran Di Masa Pandemi COVID-19

2021 ◽  
Vol 2 (4) ◽  
pp. 113-120
Author(s):  
Athaya Taufiqy
Keyword(s):  
Mental Health ◽  
Medical Students ◽  
Literature Review ◽  
World Health ◽  
Vulnerable Groups ◽  
Future Research ◽  
Learning Material ◽  
Learning Programs ◽  
Learning Platforms ◽  
Health Organization

December 2019, COVID-19 was first reported in Wuhan, Hubei Province, China. March 11, 2020, the World Health Organization declared COVID-19 a worldwide pandemic. The COVID-19 pandemic has focused attention on the mental health of the various affected populations, medical students being one of the more vulnerable groups. Therefore, this literature review aims to find out how the mental health of Faculty of Medicine students during the COVID-19 pandemic, so that it can be used as learning material to always maintain mental health stability. The method used in this study is a literature review and literature search which was carried out by collecting several electronic journals such as PubMed, NCBI and Google Scholar. Conducted by reviewing journals related to the mental health of medical faculty students during the COVID-19 pandemic. This study involved 49 library sources from 2018-2020. From 7,143 students, 0.9% of them experienced severe anxiety, 2.7% moderate, and 21.3% experienced mild anxiety. In addition, delay in academic activities is a risk factor for experiencing symptoms of anxiety. 40% of students also experience financial difficulties, in terms of e-learning platforms, this problem is a challenge for medical students because financial and social factors can be an obstacle to the development and implementation of effective online learning programs. Future research is urgently needed to provide a better explanation of the tips needed for students in adapting to the changes that occur in order to lead a mentally healthy life in the midst of the COVID-19 pandemic.

scholarly journals A Case of Polyneuropathy Following a Single Dose of Diethylcarbamazine and Albendazole During Mass Administration of Drug - A Case Report

1970 ◽  
Vol 1 (1) ◽  
pp. 56-58
Author(s):  
SC Kohli ◽  
UK Shrestha ◽  
VM Alurkar ◽  
A Maskey ◽  
M Parajuli ◽  
...  
Keyword(s):  
Abdominal Pain ◽  
Single Dose ◽  
Case Report ◽  
Side Effects ◽  
World Health Organization ◽  
Mass Drug Administration ◽  
World Health ◽  
Medical Sciences ◽  
The World ◽  
Health Organization

The global program to eliminate Lymphatic Filariasis created by The World Health organization in 1997 is based on mass administration of single annual doses of diethylcarbamazine ( DEC) plus albendazole in non African regions and of albendazole plus ivermectin in Africa. The usual side effects of DEC treatment include fever, chills, arthralgia, headaches, nausea, and vomiting. Albendazole is associated with relatively few side effects consisting of occasional nausea, vomiting, abdominal pain, headache, reversible alopecia, elevated aminotransferases and rarely leucopenia and rash. We report a case of polyneuropathy in a young individual following DEC and albendazole during mass drug administration. Keywords: Albendazole; DEC; Polyneuropathy. DOI: http://dx.doi.org/10.3126/njms.v1i1.5800   Nepal Journal of Medical Sciences. 2012; 1(1): 56-58

scholarly journals Mental healthcare in Hungary: contradictions and possibilities

2010 ◽  
Vol 7 (2) ◽  
pp. 36-38 ◽  
Author(s):  
Tamás Kurimay
Keyword(s):  
Health Spending ◽  
Mental Healthcare ◽  
World Health ◽  
Minority Population ◽  
Official Language ◽  
The European Union ◽  
Middle Income ◽  
The Republic ◽  
Health Organization ◽  
The Uk

The Republic of Hungary is a landlocked country of 93000 km2 in central Europe; it is bordered by Austria, Slovakia, Ukraine, Romania, Serbia, Croatia and Slovenia. Its official language is Hungarian. Hungary joined the European Union (EU) in 2004. About 90% of the population of c. 10 million is ethnically Hungarian, with Roma comprising the largest minority population (6–8%). Currently classified as a middle-income country with a gross domestic product (GDP) of $191.7 billion (2007 figure), Hungary's total health spending accounted for 7.4% of GDP in 2007, less than the average of 8.9% among member states of the Organisation for Economic Co-operation and Development (OECD, 2009). The proportion of the total health budget for mental health is 5.1%, which is low when compared with, for instance, the UK (England and Wales 13.8%, Scotland 9.5%) (World Health Organization, 2008, p. 118, Fig. 8.1).

scholarly journals Adolescent mothers’ utilisation of reproductive health services in the Gauteng province of the republic of South Africa

Curationis ◽  
2000 ◽  
Vol 23 (3) ◽  
Author(s):  
VJ Ehlers ◽  
T Maja ◽  
E Sellers ◽  
M Gololo
Keyword(s):  
South Africa ◽  
Reproductive Health ◽  
Adolescent Mothers ◽  
Termination Of Pregnancy ◽  
World Health ◽  
Reproductive Health Services ◽  
Gauteng Province ◽  
Emergency Contraceptive ◽  
The Republic ◽  
Health Organization

A financial grant was received from the World Health Organization (WHO) during 1998 to establish whether adolescent mothers (aged 19 or younger at the birth of their babies) utilized contraceptive, emergency contraceptive and termination of pregnancy (TOP) services in the Republic of South Africa (RSA). This report refers to data obtained from 111 questionnaires completed by dolescent mothers between January 2000 and May 2000 in the Gauteng Province; 61 in the Pretoria and 50 in the Garankuwa areas, and excluding the 12 completed questionnaires used foi pretesting the research instrument. The biographic data of the 111 adolescent mothers indicated that the minority were married, employed or earned sufficient income to care for themselves and their babies. However, the minority used contraceptives prior to conception, none used emergency contraceptives or termination of pregnancy (TOP) services. The minority attended ante-natal clinics five or more times during their pregnancies, and a negligible number indicated that they had ever been treated for sexually transmitted diseases (STDs). These findings indicate that the 111 adolescent mothers in Gauteng who participated in this survey did not make optimum use of the available reproductive health (RH) care services. Education about sex, pregnancy and contraceptives should commence at the age of 10, but no later than the age of 12 as the majority of respondents did not have the necessary knowledge to make informed decisions about their futures. The accessibility of contraceptive, emergency contraceptive and TOP services for adolescents should be investigated in specific areas and attempts made to enhance such accessi- bility. This might necessitate offering these services over weeker| ds or during evenings when school girls could attend without fear of meeting their mothers, aunts or teachers at these clinics.

scholarly journals Study on Highly Active Anti- Retroviral Therapy: prescription pattern and side effects

2012 ◽  
Vol 26 (1) ◽  
pp. 12-18
Author(s):  
Sujata Sapkota ◽  
Rajani Shakya ◽  
Basudev Pandey
Keyword(s):  
Side Effects ◽  
Drug Regimen ◽  
World Health ◽  
Management Tools ◽  
Prescription Pattern ◽  
Highly Active ◽  
Regimen Change ◽  
Initial Regimen ◽  
Health Organization ◽  
Multiple Drugs

Since the introduction of Highly Active Anti Retroviral therapy (HAART) by World Health Organization in 1996, it has been the employed method of drug use in HIV management. Involvement of multiple drugs in the regimen, has also invited multiple complications and side effects is one of them. High chances of occurrence of side effects has called for the need of proper identification and therapy management tools for each HAART user and has highlighted the importance of individualized drug therapy. The aim of the study the prescription pattern of the HAART regimen; frequency of regimen change and its major causes; and the side- effects from HAART. The study was conducted in the ART Clinic of SukraRaj Tropical & Infectious Disease Hospital, Teku. 109 patients, who came to the clinic to refill their prescription, were interviewed by the researcher. After interview, medication file of each patient was reviewed to study the prescribed drug regimen, drug changes and identified reasons for the drug change (as identified by the physicians and recorded in patient medication file); reported side effect experience and laboratory reports were analyzed to study the effect of the HAART regimen on hemoglobin and Alanine Aminotransferase enzyme. The study revealed that the most prescribed HAART regimen constituted a combination of Zidovudine, Lamivudine and Nevirapine. 52% of the patients reported having experienced side effects from HAART. 23.85% patients had to have their initial regimen changed because of drug toxicity. Nausea (15.6%), vertigo (14.7%), decreased hemoglobin (11.9%), skin rash/ allergy (9.2%) were the major side effects experience reported by the patients. In addition to some side effects like nausea, vertigo etc; decrease in the level of hemoglobin after the initiation of HAART was evident. Decrease in Zidovudine containing regimen, during the regimen change was apparent and was mostly related to its hemoglobin lowering activity. DOI: http://dx.doi.org/10.3126/jnpa.v26i1.6630 JNPA. XXVI(1) 2012 12-18

Sign in / Sign up

Export Citation Format

Share Document